-
LOCALLY SOURCED
To find and license promising
development candidates from
domestic biotech/pharma
companies and universities -
REGIONALLY FINANCED
To establish sources of financing
from regional investment
communities -
GLOBALLY DEVELOPED
To develop assets up to human
PoC(Proof of Concept) globally
Pipeline
We have initially focused on small molecular entities (SME) for the treatment of inflammatory and fibrotic diseases and are gradually expanding our interests to the immuno-oncology field with advanced modalities.
News
Boehringer Ingelheim Expands Idiopathic Pulmonary Fibrosis (IPF) Pipeline Through Collaboration and License Agreement with Bridge Biotherapeutics
o Boehringer Ingelheim has entered into a collaboration and global license agreement for Bridge Biotherapeutics’s autotaxin inhibitor BBT-877 to be developed for fibrosing interstitial lung diseases including IPF o With this new partnership Boehringer Ingelheim further expands its commitment to bring new treatments to patients with fibrosing interstitial lung diseases including IPF o Bridge Bi...
Read More-
LEARN MORE ABOUT US
-
CONTACT INFORMATION
HQ: Suite 903-2, Bldg B, Innovalley, 253 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13486 Republic of Korea
US Office: Bridge Biotherapeutics, Inc. in JLABS@TMC, 2450 Holcombe Blvd. Houston, TX 77021, USADirector, Jong-jin Lim (jong-jin.lim@bridgebiorx.com)
Manager, Joengbin Ahn (Joengbin.ahn@bridgebiorx.com)